Lilly gets sought-after FDA designation for Alzheimer's candidate

The US FDA is accompanying the recent approval of Biogen's Alzheimer's treatment with a breakthrough therapy designation for another potential treatment of the disease.

Photo: Mike Blake/REUTERS / X00030

Eli Lilly's drug candidate donanemab treating Alzheimer's disease has received breakthrough therapy status at the US Food and Drug Administration, according to a press release from Eli Lilly.

The coveted designation is given to drug candidates treating serious or life-threatening diseases with preliminary data indicating that this drug can significantly improve treatment opportunities.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Trial banner

Latest news

See all jobs